Short answer: when a team says, “We’ll try 510(k),” it usually means the regulatory strategy is not fully developed.

A 510(k) is not something you “try.” It is something you qualify for.

Under the framework of the U.S. Food and Drug Administration, the 510(k) pathway depends on a very specific standard: substantial equivalence to a legally marketed predicate device.

If that logic is not solid, the pathway collapses.

Why “We’ll Try 510(k)” Signals Weak Strategy
1. It Suggests Predicate Assumptions Haven’t Been Proven

A valid 510(k) requires:

Same intended use as the predicate

Similar technological characteristics

No new questions of safety or effectiveness

If those elements are not clearly documented and defensible, the application is vulnerable.

Saying “we’ll try” often means:

Predicate searches were surface-level

Technological differences were not deeply analyzed

Risk escalation wasn’t fully assessed

That is not a strategy. That is hope.

2. It Ignores the Risk of Refuse-to-Accept (RTA)

FDA can refuse to accept a 510(k) submission if:

Required elements are missing

Substantial equivalence is poorly justified

Testing does not align with technological differences

An RTA decision is not a minor setback. It costs:

Months of delay

Additional consulting fees

Investor confidence

“We’ll try 510(k)” does not account for this risk.

3. It Underestimates Technological Differences

Many teams believe that small changes do not matter.

But FDA evaluates whether differences:

Introduce new mechanisms of action

Change performance characteristics

Alter risk profile

If the device includes:

AI-based functionality

New materials

Expanded clinical claims

Different energy delivery

Those differences may disqualify 510(k).

This is where optimism becomes expensive.

4. It Distorts Timeline and Budget Planning

If 510(k) is assumed but not validated, downstream planning becomes flawed:

Testing budgets are underestimated

Clinical study planning may be deferred

Investor projections become unrealistic

If the pathway later shifts to De Novo or PMA, cost exposure increases dramatically.

That shift rarely happens quietly. It happens during diligence or FDA review.

What a Strong 510(k) Strategy Looks Like

A defensible 510(k) plan includes:

Structured predicate identification

Detailed technological comparison

Risk analysis tied to differences

Testing plans directly addressing risk gaps

Clear intended use alignment

It does not rely on “similar enough.”

It relies on documented equivalence.

Where Kandih Comes In

This is where Kandih Group provides structured predicate stress-testing.

Kandih supports teams by:

Conducting deep predicate landscape analysis

Comparing technological characteristics line-by-line

Identifying hidden safety questions

Evaluating whether differences introduce new risk categories

Modeling fallback pathways if 510(k) fails

Building defensible substantial equivalence arguments

Instead of “trying” 510(k), teams know whether it is viable before capital is deployed.

That protects:

Development timelines

Investor confidence

Regulatory credibility

Bottom Line

“We’ll try 510(k)” signals uncertainty.

Strong regulatory strategy does not guess.
It validates.

If 510(k) is viable, it should be defendable.
If it is not, the pivot should happen early—not after submission.

That is how regulatory discipline prevents expensive surprises.

References

FDA – Premarket Notification 510(k)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k

FDA – Refuse to Accept Policy for 510(k)s
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-accept-policy-510ks

FDA – Substantial Equivalence in Premarket Notifications (510(k))
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/substantial-equivalence-premarket-notifications-510k

FDA – Classify Your Medical Device
https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device